TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01399073

Intervention type: BEHAVIORAL
Intervention: virtual reality setup
Description: testing for neglect in a virtual reality setup

Intervention type: BEHAVIORAL
Intervention: virtual reality setup
Description: testing for neglect in a virtual reality setup

Intervention type: BEHAVIORAL
Intervention: virtual reality setup
Description: testing for neglect in a virtual reality setup

Intervention type: BEHAVIORAL
Intervention: paper and pencil tests
Description: testing for neglect with the classical paper-and-pencil tests

Intervention type: BEHAVIORAL
Intervention: paper and pencil tests
Description: testing for neglect with the classical paper-and-pencil tests

Intervention type: BEHAVIORAL
Intervention: paper and pencil tests
Description: testing for neglect with the classical paper-and-pencil tests

Intervention type: OTHER
Intervention: c-mri
Description: structural and functional (resting state) imaging

Intervention type: OTHER
Intervention: c-mri
Description: structural and functional (resting state) imaging

Intervention type: OTHER
Intervention: c-mri
Description: structural and functional (resting state) imaging
Study: NCT02016755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HGF Plasmid
Description: Intramuscular injection in the affected limb.
Study: NCT00765999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
Study: NCT00387868

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin and etoposide
Description: Cisplatin: 50mg/m2 - administered on days 1,8,29\&36 Etoposide: 50 mg/m2 - administered on days 1-5 \& 29-33

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin and etoposide
Description: Cisplatin: 50mg/m2 - administered on days 1,8,29\&36 Etoposide: 50 mg/m2 - administered on days 1-5 \& 29-33

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Resection
Description: Resection will take place 4-8 weeks after completion of radiotherapy.

Intervention type: RADIATION
Group type: OTHER
Intervention: Concurrent Radiotherapy
Description: Preoperative External Beam Radiotherapy
Study: NCT00306228

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postfibrinolysis percutaneous coronary intervention
Description: implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
Study: NCT00298233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).
Study: NCT02859194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Veno-veno-arterial ECMO
Study: NCT01333475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206 + AZD6244
Description: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206 + AZD6244
Description: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
Study: NCT00435825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.
Study: NCT04196582

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of LMA Gastro Airway® and Gastro-Laryngeal Tube in patients who will undergo biliopancreatic procedures.
Description: comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of LMA Gastro Airway® and Gastro-Laryngeal Tube in patients who will undergo biliopancreatic procedures.
Description: comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures
Study: NCT00350194

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 fatty acids
Description: Total of 1.8 grams of EPA +DHA in the form of fish oil capsules (3/day)
Study: NCT02258633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive interview and tailored family centered seatbelt safety intervention
Study: NCT01136837

Intervention type: OTHER
Intervention: primary pcı
Study: NCT02913651

Intervention type: DEVICE
Intervention: Polysomnography
Description: The polysomnography, for both groups, was performed accordance with standard practice

Intervention type: DEVICE
Intervention: Polysomnography
Description: The polysomnography, for both groups, was performed accordance with standard practice
Study: NCT02780999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whale orthosis
Description: Participants will be teach how to use the Whale orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colditz orthosis
Description: Participants will be teach how to use the Colditz orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain.
Study: NCT03923816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).&Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).
Description: comparison of two intraoperative fluid strategies upon hepatic outcome in hepatobiliary surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).&Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).
Description: comparison of two intraoperative fluid strategies upon hepatic outcome in hepatobiliary surgery
Study: NCT02996448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDV-3A
Description: A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.
Study: NCT02015299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: one tablet linagliptin 5 mg/day for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet matching placebo/day for 26 weeks
Study: NCT02745379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BFPSCs+ DFDBA+ PRF

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DFDBA + PRF
Study: NCT01272934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: Topical gel 1%-4 times daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical gel-4 times daily
Study: NCT01681693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects will be given an oral dose of metformin once per day for two days.
Study: NCT00911365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous mesenchymal stem cells
Description: 4\*107 stem cell (100ml) Intra arterial infusion/ one time, then 4\*107 stem cell(100ml)Intravenous infusion 3 times/monthly~-\> Total four times

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: saline
Study: NCT00803634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine
Description: Clevidipine was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative IV antihypertensive agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Patients who received an alternative antihypertensive agent along with the study drug were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered approximately 1 hour prior to the termination of clevidipine with study drug down-titrated or terminated in order to maintain the desired blood pressure level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care IV antihypertensive
Description: SOC IV antihypertensive agent will be administered for a minimum of 30 min and, if medically warranted, may continue beyond 96 hours at the investigator's discretion. As with clevidipine, the SOC agent was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Higher dose titration rates were required to be attempted prior to making the decision to switch to or add on an alternative antihypertensive agent(s). Patients who received an alternative antihypertensive agent with SOC were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered per institutional practice.
Study: NCT03818217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coach Pepper group
Description: Robot Pepper's height is 1.20 meters and it weighs 28 kilograms. Pepper's operation time is about 12 hours.~Pepper will be called as Coach Pepper because s/he is virtually connected via web interfaces with a theratainment app including cognitive and physical training .

Intervention type: DEVICE
Group type: OTHER
Intervention: Tablet group
Description: The Tablet provides a theratainment app including cognitive and physical training.
Study: NCT01175226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTA798
Description: BTA798 twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily
Study: NCT00733265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6140
Description: single oral dose
Study: NCT00976313

Intervention type: PROCEDURE
Intervention: Assessment of urinary micturition after thoracotomy
Description: Post residual urine volume and voided volume will be assessed with Bladder Scan™ BVI 6100 (Bladder scan, Bothell, WA, USA) will be performed the day before surgery and on day 2 after surgery, with epidural analgesia within segments T2-4 to T10 21,22. Bladder sensitivity will be assessed at strong desire to void. On day 2 the bladder will be filled through the transurethral catheter till the patient signalised a strong desire to void, then the catheter will be removed and spontaneous micturition will be attempted. Voided volume and post void residual will be assessed.
Study: NCT00861341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30mg Pioglitazone x1
Study: NCT01747759

Intervention type: OTHER
Group type: OTHER
Intervention: Kruskal-Wallis and qualitative parameters

Intervention type: OTHER
Group type: OTHER
Intervention: Kruskal-Wallis and qualitative parameters
Study: NCT00141440

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mechanical ventilation
Description: evaluated the effect of two different cycling off criteria on breathing pattern, respiratory effort, and gas exchange in patients with chronic obstructive pulmonary disease
Study: NCT03779386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: music during labor and delivery
Study: NCT02268591

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Stimulator
Description: A non invasive brain stimulation which delivers low amplitude current through scalp electrodes by a Transcranial Stimulator
Study: NCT00976313

Intervention type: OTHER
Intervention: International Prostate Symptom Score
Description: International Prostate Symptom Score (IPSS) for assessment of lower urinary tract symptoms (LUTS) preoperatively

Intervention type: OTHER
Intervention: International Prostate Symptom Score
Description: International Prostate Symptom Score (IPSS) for assessment of lower urinary tract symptoms (LUTS) preoperatively
Study: NCT00634192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tobramycin
Description: 1x300mg/d inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tobramycin
Description: 2x300mg/d inhaled
Study: NCT03344991

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardboard Cot Care
Description: When ready to be weaned from radiant warmer, infant will be placed in a reflective film-lined cot for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
Study: NCT04101084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Rocking sessions in a safe rocking chair for 2 hours daily for six weeks
Study: NCT00800722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin Treatment of Port Wine Stain
Description: Treatment of Port Wine Stain
Study: NCT02391922

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: First aid instructions by mobile phone

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: First aid instructions by mobile phone
Study: NCT06701695

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular Injection (PAI)
Description: Patients in the periarticular injection group were administered a 100 mL periarticular solution comprising 200 mg of bupivacaine (40 mL), 60 mg of ketorolac (2 mL), 8 mg of dexamethasone (2 mL), 2 mg of 1:1000 epinephrine (2 mL), and standard saline solution (54 mL). This solution was prepared in two 50 mL syringes. The first syringe containing 50 mL of the cocktail was injected into the capsule and gluteal muscles prior to femoral stem insertion. Following joint capsule closure, the second syringe containing 50 mL of the periarticular injection cocktail was infiltrated into the fascia lata muscle, subcutaneous tissue, and wound layers.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control (Standard treatment)
Description: The control group received the conventional treatment protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control (Standard treatment)
Description: The control group received the conventional treatment protocol.
Study: NCT06702254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Psychological manualized treatment with CBT and ACT
Description: The intervention is brief and centered around four therapeutic sessions that can be extended or shortened depending on how long patients are hospitalized. Core techniques from CBT and ACT are included in the manual and consists of behavioral activation and values and unhelpful thoughts. Nursing staff on these wards have received training in the manual parallel with supervision which is not given in the treatment as usual wards. The wards that have not received the intervention will be offered this at the end of their TAU period.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: This treatment as usual can consist of medication, brief talks, leisure activity on the wards.
Study: NCT03626857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Description: The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of at least 40\& of the contralateral MVIC.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise (ECC)
Description: 4 sets of 10 repetitions of an eccentric leg press exercise performed at 70-90% of the 1 repetition maximum

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation (NMES) placebo
Description: The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of 10-20% of the contralateral MVIC.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eccentric Exercise (ECC) placebo
Description: 4 sets of 10 repetitions of an eccentric leg press exercise performed at 10-20% of the 1 repetition maximum
Study: NCT03914937

Intervention type: OTHER
Intervention: Virtual reality
Description: A virtual reality device will be worn over the eyes that allows the patient to feel that they are at a quiet seaside beach.

Intervention type: OTHER
Intervention: Music
Description: Music of the patient's choice will be played
Study: NCT04519203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPI
Description: Either standard monitoring alone or added with SPI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard monitoring alone
Study: NCT04057898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-166
Description: Subjects will take MN-166 for 12 months followed by a 6-month open-label extension phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will take matching placebo for 12 months followed by a 6-month open-label extension phase.
Study: NCT03625752

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Active tDCS + Active TUS
Description: Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
Study: NCT01284231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-565
Description: MEDI-565 will be administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-565
Description: 20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-565
Description: 20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-565
Description: 20 Subjects with refractory Gastroesophageal cancer to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.